Sabra Health Care REIT, Inc. filings document the reporting obligations of a Nasdaq-listed healthcare REIT that owns and invests in healthcare real estate through subsidiaries. Its 8-K reports cover operating results, supplemental information packages, non-GAAP financial measure reconciliations, Regulation FD materials, capital-structure events and material definitive agreements.
Proxy materials describe board and shareholder governance for the Maryland corporation. Other disclosures address common stock listed under the SBRA symbol, equity distribution arrangements, debt redemption notices, related financing arrangements and risk or governance matters tied to the company’s REIT structure and healthcare real estate portfolio.
Sabra Health Care REIT, Inc. reported third-quarter revenue of $249.6 million, versus $190.0 million a year earlier, and net income attributable to Sabra of $28.6 million, versus $22.5 million. For the first nine months, revenue was $707.2 million compared with $562.7 million, while net income attributable to Sabra was $44.3 million versus $128.4 million.
For the nine-month period, Sabra recorded a $104.6 million provision for loan losses and other reserves, compared with a $640,000 recovery a year earlier. It received a reduced $200.0 million cash payment in full satisfaction of a $300.0 million Recovery Centers of America mortgage loan and wrote off $100.0 million. Operating cash flow was $313.2 million, compared with $261.2 million.
Sabra acquired 14 SHOP communities, two skilled nursing/transitional care facilities, and exercised its option to acquire one additional such facility for aggregate consideration of $511.4 million during the nine months. It sold 14 properties for $166.9 million net of closing costs. Sabra reported compliance with applicable financial covenants as of September 30, 2026. On November 2, the board declared a $0.30 per-share dividend payable November 30 to holders of record November 13.
Sabra Health Care REIT, Inc. (SBRA) reported third-quarter 2026 revenue of $249.565 million, compared with $190.037 million a year earlier, and net income attributable to Sabra of $28.607 million, versus $22.538 million. Diluted net income per share was $0.11, compared with $0.09; FFO and normalized FFO per diluted share were $0.40 and $0.39. Same-property SHOP Cash NOI increased 14.6% year over year.
Sabra closed on seven SHOP communities for $222.8 million at an estimated 7.7% yield. It also reported $425 million of awarded investments in the Letter of Intent or later stage, which it expects to fund if consummated. A transition of 26 properties formerly leased to Avamere took effect October 1; annualized cash rent increased to $53 million from $48 million.
Sabra declared a quarterly dividend of $0.30 per common share. Updated 2026 guidance includes net income of $0.265–$0.275 and normalized FFO of $1.540–$1.550 per diluted share. Nine-month net income attributable to Sabra was $44.285 million, compared with $128.384 million in 2025.
Sabra Health Care REIT, Inc. (SBRA) reported that Chair, CEO and President Richard K. Matros, through the R&A Matros Revocable Trust, sold 200,000 shares of common stock on September 8, 2026 at a weighted average price of about $20.83 per share under a Rule 10b5-1 trading plan adopted on June 8, 2026. After this sale, the trust held 1,657,686 shares of common stock, and Matros also held 956,268 stock units that will settle on a one-for-one basis in Sabra common stock.
Sabra Health Care REIT, Inc. (SBRA) discloses that its CEO, Richard K. Matros, has filed a notice of proposed sale under Rule 144 for up to 200,000 shares of common stock through Merrill Lynch. The shares have an aggregate market value of $4,150,000 and are part of a share class with 255,462,756 shares outstanding, with sales expected to begin on or about September 8, 2026 on NASDAQ. The notice identifies multiple underlying awards classified as Restricted Stock Units originally granted between 2013 and 2017, including blocks of 7,514 and 29,020 shares, each indicated for cash settlement on September 8, 2026.
Sabra Health Care REIT, Inc. (symbol: SBRA) is the issuer of record for a Form 4 filing submitted to the SEC. Smith Darrin reported acquisition or exercise transactions in this Form 4 filing.
Sabra Health Care REIT, Inc. (SBRA) reported that Executive VP, CIO & Secretary Darrin Smith received a grant of 495 stock units of common stock on August 31, 2026 as a dividend equivalent on previously granted units under the 2009 Performance Incentive Plan. Following this award, he directly holds 116,919 stock units and shares, including 34,182 stock units payable in common stock on a one-for-one basis, all subject to the same vesting terms as the original units. No Rule 10b5-1 trading plan is reported.
Sabra Health Care REIT, Inc. (symbol: SBRA) is the issuer of record for a Form 4 filing submitted to the SEC. Malehorn Jeffrey A. reported acquisition or exercise transactions in this Form 4 filing.
Sabra Health Care REIT, Inc. (SBRA) director Jeffrey A. Malehorn received a grant of 791 stock units of common stock-equivalent on August 31, 2026 as a dividend-equivalent credit under the company’s 2009 Performance Incentive Plan. Following this award, he holds 117,137 stock units, including unvested and deferred units.
Sabra Health Care REIT, Inc. (SBRA) reported that director Ann Kono acquired 791 stock units of common stock on August 31, 2026 as a dividend equivalent credit under Sabra’s 2009 Performance Incentive Plan. Following this award, she directly holds 68,977 stock units, each representing the right to receive one share of common stock.
Sabra Health Care REIT, Inc. (SBRA) reported that director Lynne S. Katzmann received a grant of 791 stock units of common stock on August 31, 2026, as a grant/award acquisition with no cash price per share. The stock units were credited as dividend equivalent payments on previously granted stock units outstanding under Sabra’s 2009 Performance Incentive Plan and will vest and become payable on the same terms as the original stock units. Following this award, Katzmann holds a reported total of 86,912 stock units, including 7,027 unvested stock units and 47,553 stock units that have vested but for which payment has been deferred, with each stock unit representing the right to receive one share of Sabra common stock.
Sabra Health Care REIT, Inc. (symbol: SBRA) is the issuer of record for a Form 4 filing submitted to the SEC. FOSTER MICHAEL J reported acquisition or exercise transactions in this Form 4 filing.
Sabra Health Care REIT, Inc. director Michael J. Foster reported receiving a grant of 791 stock units tied to common stock on August 31, 2026. According to the company’s equity plan, these units were credited as dividend equivalent payments on previously granted stock units and will vest and be paid on the same schedule as those original units.
After this award, Foster holds 82,834 stock units directly, including 7,027 unvested stock units and 47,553 vested but deferred stock units, each representing the right to receive one share of common stock. He also has 42,411.745 shares held indirectly through a 401(k) plan. No transactions are reported as made under a Rule 10b5-1 trading plan.
Sabra Health Care REIT, Inc. (SBRA) director Catherine Cusack reported an acquisition of 791 stock units of common stock on August 31, 2026, as a grant or award. The units were credited as dividend equivalent payments on previously granted stock units under Sabra’s 2009 Performance Incentive Plan.
After this credit, Cusack directly holds 82,847 stock units, including 7,027 unvested stock units and 47,553 vested stock units for which payment has been deferred. Each stock unit represents the right to receive one share of Sabra common stock.